Recent advances on blinatumomab for acute lymphoblastic leukemia
AbstractAlthough complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody –drug conjugates and chimeric antigen receptor T cell therapy are changing the therapy landscape for B- ALL. Blinatumomab, a bi-specific T cell engager, has been approved for patients with relapsed/refractory and minimal residual disease positive B-ALL. This review summarized data from recent clin ical trials of blinatumomab for B-ALL treatment.
The aim of the study was to determine the frequency of nonsyndromic cleft lip and/or palate (NSCL/P) in the first-degree relatives of patients with acute lymphoblastic leukemia (ALL).
Epigenomics, Ahead of Print.
Thiopurines, including mercaptopurine, are a cornerstone of modern maintenance therapy for childhood acute lymphoblastic leukemia (ALL) and various other diseases. Thiopurine methyltransferase (TPMT) is a pivotal enzyme in the degradation of toxic thiopurine metabolites. Individuals heterozygous for inactivating TPMT variants (about 10% of the European and American population) require modest decreases in thiopurine dosing, whereas those with homozygous defects tolerate only about one-tenth the conventional dose.
Contributors : Anica Wandler ; Benjamin Huang ; James Downing ; Jinghui Zhang ; Kevin ShannonSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusDespite decades of clinical use, mechanisms of glucocorticoid resistance are poorly understood. We treated primary murine T lineage acute lymphoblastic leukemias (T-ALLs) with the glucocorticoid dexamethasone (DEX) alone and in combination with the pan-PI3 kinase inhibitor GDC-0941 and observed a robust response to DEX that was modestly enhanced by GDC-0941. Continuous in vivo treatment invariably resulted in outgrowth of drug-resistant clones, ~...
Condition: Acute Lymphoblastic Leukemia ,Lymphomas Intervention: Biological: Anti-CD19 CAR-T Sponsor: The First Affiliated Hospital of Nanchang University Recruiting
Publication date: December 2019Source: Cytotherapy, Volume 21, Issue 12Author(s): Seshu Tyagarajan, David Schmitt, Christopher Acker, Erik RutjensAbstractTisagenlecleucel, a CD19-specific autologous chimeric antigen receptor (CAR)–T cell therapy, is efficacious for the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The tisagenlecleucel manufacturing process was initially developed in an academic setting and subsequently transferred to industry for qualification, validation and scaling up for global clinical trials and commercial distribution. Use of f...
Publication date: 9 December 2019Source: Cancer Cell, Volume 36, Issue 6Author(s): Andrei V. Krivtsov, Kathryn Evans, Jayant Y. Gadrey, Benjamin K. Eschle, Charlie Hatton, Hannah J. Uckelmann, Kenneth N. Ross, Florian Perner, Sarah N. Olsen, Tara Pritchard, Lisa McDermott, Connor D. Jones, Duohui Jing, Ali Braytee, Diego Chacon, Eric Earley, Brian M. McKeever, David Claremon, Andrew J. Gifford, Heather J. LeeSummaryInhibition of the Menin (MEN1) and MLL (MLL1, KMT2A) interaction is a potential therapeutic strategy for MLL-rearranged (MLL-r) leukemia. Structure-based design yielded the potent, highly selective, and orally b...
Blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed.